CombiGene AB (publ) (COMBI.ST)
SEK 2.38
(-2.46%)
SEK 2.38
(-2.46%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 44.14 Million SEK | -5.39% |
| 2022 | 46.65 Million SEK | -26.46% |
| 2021 | 63.44 Million SEK | 116.1% |
| 2020 | 29.36 Million SEK | 59.26% |
| 2019 | 18.43 Million SEK | 39.26% |
| 2018 | 13.23 Million SEK | 10.7% |
| 2017 | 11.95 Million SEK | 37.98% |
| 2016 | 8.66 Million SEK | 38.57% |
| 2015 | 6.25 Million SEK | 550.56% |
| 2014 | 961.36 Thousand SEK | 3396.5% |
| 2013 | 27.49 Thousand SEK | 181.74% |
| 2012 | 9759.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 7.29 Million SEK | -49.79% |
| 2024 Q1 | 14.52 Million SEK | 46.74% |
| 2023 Q1 | 16.78 Million SEK | 71.09% |
| 2023 Q4 | 9.89 Million SEK | 3.45% |
| 2023 Q3 | 9.56 Million SEK | 18.47% |
| 2023 FY | 44.14 Million SEK | -5.39% |
| 2023 Q2 | 8.07 Million SEK | -51.9% |
| 2022 Q3 | 9.57 Million SEK | 4212.61% |
| 2022 FY | 46.65 Million SEK | -26.46% |
| 2022 Q1 | 14.08 Million SEK | -47.76% |
| 2022 Q2 | 222 Thousand SEK | -98.42% |
| 2022 Q4 | 9.81 Million SEK | 2.47% |
| 2021 Q2 | 15.4 Million SEK | 41.88% |
| 2021 Q1 | 10.85 Million SEK | -10.76% |
| 2021 Q3 | 10.22 Million SEK | -33.62% |
| 2021 Q4 | 26.96 Million SEK | 163.71% |
| 2021 FY | 63.44 Million SEK | 116.1% |
| 2020 Q3 | 6.41 Million SEK | 78.7% |
| 2020 Q2 | 3.59 Million SEK | -50.04% |
| 2020 Q1 | 7.18 Million SEK | -24.9% |
| 2020 FY | 29.36 Million SEK | 59.26% |
| 2020 Q4 | 12.16 Million SEK | 89.57% |
| 2019 Q3 | 3.57 Million SEK | 27.19% |
| 2019 Q4 | 9.57 Million SEK | 167.44% |
| 2019 FY | 18.43 Million SEK | 39.26% |
| 2019 Q1 | 2.47 Million SEK | -21.22% |
| 2019 Q2 | 2.81 Million SEK | 13.83% |
| 2018 Q1 | 1.99 Million SEK | -39.3% |
| 2018 FY | 13.23 Million SEK | 10.7% |
| 2018 Q4 | 3.13 Million SEK | -47.18% |
| 2018 Q3 | 5.94 Million SEK | 175.17% |
| 2018 Q2 | 2.15 Million SEK | 8.0% |
| 2017 Q1 | 2.75 Million SEK | 615.69% |
| 2017 FY | 11.95 Million SEK | 37.98% |
| 2017 Q4 | 3.29 Million SEK | 16.98% |
| 2017 Q3 | 2.81 Million SEK | -9.22% |
| 2017 Q2 | 3.1 Million SEK | 12.72% |
| 2016 Q1 | 290.99 Thousand SEK | -88.74% |
| 2016 FY | 8.66 Million SEK | 38.57% |
| 2016 Q4 | 384.38 Thousand SEK | -5.79% |
| 2016 Q3 | 407.99 Thousand SEK | 10.27% |
| 2016 Q2 | 370 Thousand SEK | 27.15% |
| 2015 Q3 | 1.11 Million SEK | -35.31% |
| 2015 Q1 | 1.05 Million SEK | 17.42% |
| 2015 FY | 6.25 Million SEK | 550.56% |
| 2015 Q4 | 2.58 Million SEK | 132.41% |
| 2015 Q2 | 1.71 Million SEK | 62.78% |
| 2014 Q3 | 46 Thousand SEK | 0.0% |
| 2014 Q4 | 899.36 Thousand SEK | 1855.14% |
| 2014 Q2 | - SEK | -100.0% |
| 2014 Q1 | 16 Thousand SEK | 0.0% |
| 2014 FY | 961.36 Thousand SEK | 3396.5% |
| 2013 FY | 27.49 Thousand SEK | 181.74% |
| 2012 FY | 9759.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.085% |
| AcouSort AB (publ) | 25.87 Million SEK | -70.599% |
| Active Biotech AB (publ) | 44.8 Million SEK | 1.484% |
| Alzinova AB (publ) | 36.39 Million SEK | -21.288% |
| Amniotics AB (publ) | 29.07 Million SEK | -51.844% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -201.263% |
| BioArctic AB (publ) | 89.62 Million SEK | 50.747% |
| Camurus AB (publ) | 1.05 Billion SEK | 95.834% |
| Cantargia AB (publ) | 290.01 Million SEK | 84.779% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -101.617% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -55.841% |
| Genovis AB (publ.) | 88.19 Million SEK | 49.948% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 61.638% |
| Mendus AB (publ) | 129.13 Million SEK | 65.816% |
| Kancera AB (publ) | 63.07 Million SEK | 30.016% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -699.857% |
| LIDDS AB (publ) | 27.75 Million SEK | -59.066% |
| Lipum AB (publ) | 37.3 Million SEK | -18.327% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -508.548% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 67.52% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -169.155% |
| NextCell Pharma AB | -576.01 Thousand SEK | 7763.654% |
| OncoZenge AB (publ) | 15.9 Million SEK | -177.549% |
| Saniona AB (publ) | 1.07 Million SEK | -3998.803% |
| Simris Alg AB (publ) | 38.64 Million SEK | -14.239% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 86.27% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 87.656% |
| Xintela AB (publ) | 57.31 Million SEK | 22.981% |
| Ziccum AB (publ) | 27.87 Million SEK | -58.347% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -507.376% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 75.709% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 69.127% |
| Intervacc AB (publ) | 79.78 Million SEK | 44.671% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 85.625% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -3.547% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -149.641% |
| Corline Biomedical AB | 30.16 Million SEK | -46.328% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 23.93% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 46.922% |
| Aptahem AB (publ) | 10.01 Million SEK | -340.87% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 67.226% |
| Fluicell AB (publ) | 28.61 Million SEK | -54.258% |
| Biovica International AB (publ) | 133.72 Million SEK | 66.988% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -123.063% |
| Abliva AB (publ) | 27.86 Million SEK | -58.416% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 77.187% |
| 2cureX AB (publ) | 36.51 Million SEK | -20.883% |
| I-Tech AB | 40.14 Million SEK | -9.953% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 94.864% |
| Cyxone AB (publ) | 28.21 Million SEK | -56.462% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 59.637% |
| Biosergen AB | 26.8 Million SEK | -64.662% |
| Nanologica AB (publ) | 69.88 Million SEK | 36.835% |
| SynAct Pharma AB | 224.49 Million SEK | 80.336% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 0.072% |
| BioInvent International AB (publ) | 441.4 Million SEK | 89.999% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -84.285% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 84.765% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -461.897% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 60.2% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -200.3% |